Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of data supporting the effective use of its high-density microarray patch ...

StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the biotechnology ...

Genocea Biosciences (NASDAQ:GNCA – Get Free Report) and Kodiak Sciences (NASDAQ:KOD – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the ...

CD4-cell counts and T-cell activation levels were determined ... and higher LPS levels were associated with greater activation of CD8 + lymphocytes. CD8 + activation also was found to be higher ...

We are thrilled to share that the first trial site has been initiated and activation of additional clinical sites continues,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-c ...

Objectives To study the biology of the conventional T cells in human enthesis. Methods CD4+ and CD8+ T cells were investigated in 25 enthesis samples using immunofluorescence, cytometrically, bulk ...

SB treatment resulted in a decreased production of IFN-γ and granzyme B in CD8+ T cells and NK cells. Moreover, SB induced IFN-γ-R1 in NK cells and CD4+ T cells in the absence of glucose both in PBMCs ...

The efficacy of CD8 T cell depletion was verified by flow cytometry through tail ... The following antibodies were used from Biolegend: CD8 (53-6.7), CD4 (RM4-5), CD25 (PC61), CD44 (IM7), CD62L ...

T cells are positioned at the frontline of the body's immune system to fight infection, cancer, and autoimmune disease. While ...

Tuberculosis remains one of the most lethal infectious diseases caused by a single pathogen. According to the latest global ...